Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Windtree Therapeutics Inc | WINT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.401299 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.401299 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.282 - 11.98 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.401299 | USD |
Windtree Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.06M | 5.15M | - | 0 | -39.21M | -7.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Windtree Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical WINT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.36 | 0.4831 | 0.355 | 0.426457 | 237,813 | 0.0413 | 11.47% |
| 1 Month | 0.36 | 0.4831 | 0.34 | 0.4055318 | 144,638 | 0.0413 | 11.47% |
| 3 Months | 0.49 | 0.521899 | 0.282 | 0.3957554 | 165,148 | -0.0887 | -18.10% |
| 6 Months | 1.38 | 1.41 | 0.282 | 0.5557655 | 195,925 | -0.9787 | -70.92% |
| 1 Year | 7.29 | 11.98 | 0.282 | 1.88 | 323,249 | -6.89 | -94.50% |
| 3 Years | 106.95 | 170.00 | 0.282 | 50.53 | 1,019,637 | -106.55 | -99.62% |
| 5 Years | 347.50 | 503.00 | 0.282 | 55.38 | 810,668 | -347.10 | -99.88% |
Windtree Therapeutics Description
| Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products. |
